Insulet Corp.

Insulet Corp.

PODD

$165.02

Updated: 05/11/2026, 01:27:04

Market Cap
$11.44B
Sector
Healthcare
Industry
Medical - Devices
Country
US

No historical data available

Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

USD
NASDAQ
CEO: Ashley McEvoy
Employees: 5,400
https://www.insulet.com
Asset Summaries
Latest generated summaries for PODD

No summaries found.

Detailed business
Evidence-backed facts extracted from the latest official annual filing.
PODD-10-k-fy2025.html2.0 MBtext/htmlENFiled 18/02/2026Period ended 31/12/2025

Business monitoring

Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.

Evidence-backed · 43 KPI observations

Revenue

N/A

FY — · Reported

Net income

$0.2B

FY 2025 · Reported

Gross margin

N/A

FY — · Reported

Free cash flow

$0.4B

FY 2025 · Calculated

R&D intensity

N/A

FY — · Reported

Share repurchases

$0.1B

FY 2025 · Reported

Earnings and cash generation
USD billions, directly sourced from inline XBRL; free cash flow is operating cash flow less capex.
Profitability and reinvestment
Margins and R&D as a percentage of revenue.
Top products and services
Products and services mentioned in the filing; a quantitative sales breakdown was not disclosed.

Other offerings mentioned without separate sales

Omnipod product platform concentration
Omnipod platform product family
Drug Delivery — Amgen Neulasta Onpro
Non-insulin Drug Delivery product line — Amgen Neulasta Onpro
Drug Delivery product line revenue recognition

Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.

Geographic footprint
What the filing identifies, separated by location role so partner manufacturing is not presented as Apple-owned factories.
1 named headquarters
2 manufacturing countries
0 individually named factories

Map layer

Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.

No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosure
Named headquarters Manufacturing partner country

Costa Rica manufacturing network

Costa Rica · Manufacturing Partner Country

95% confidence
Functions
Manufacturing, Supply Chain
Ownership
Outsourcing Partner
Products / scope
Not disclosed by country
Share of production
Not disclosed by country
Reported revenue share
Not disclosed by country
Malaysia and Costa Rica manufacturing plants. We began producing product at our new manufacturing plant in Malaysia in 2024 and are already investing in another manufacturing plant in Costa Rica

Costa Rica

Costa Rica manufacturing network

We began producing product at our new manufacturing plant in Malaysia in 2024 and are already investing in another manufacturing plant in Costa Rica to support our continued growth.

Malaysia

Malaysia manufacturing network

We began producing product at our new manufacturing plant in Malaysia in 2024 and are already investing in another manufacturing plant in Costa Rica to support our continued growth.

Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.

How the business makes money

Core business

Development, manufacture, and sale of proprietary continuous insulin delivery systems for insulin-dependent diabetes

99%
Source evidence
“primarily engaged in the development, manufacture, and sale of its proprietary continuous insulin delivery systems for people with insulin-dependent diabetes”

Omnipod product platform

Proprietary Omnipod platform — tubeless AID for insulin-dependent diabetes; Omnipod 5 integrates with Dexcom G6/G7 and Abbott Libre 2 Plus

98%
Source evidence
“primarily engaged in the development, manufacture, and sale of our proprietary Omnipod product platform, a continuous insulin delivery system for people with insulin-dependent diabetes”

Business description

Omnipod platform plus drug delivery device based on Omnipod

95%
Source evidence
“the Company’s product offering primarily consists of the Omnipod platform and a drug delivery device based on the Omnipod platform”

Omnipod 5 geographic expansion

Omnipod 5 launched in U.S. (2022), UK/Germany (2023), Netherlands/France (2024), nine more countries in 2025; available in 19 countries

95%
Source evidence
“Following the launch of Omnipod 5 in several countries in the Middle East in early 2026, Omnipod 5 is now available in 19 countries”

Single reportable segment

One reportable segment; CEO is CODM, evaluated primarily on consolidated operating income

95%
Source evidence
“Based on this assessment, the Company operates in one reportable segment. While the CODM evaluates performance and allocates resource primarily using consolidated operating income, net income is also provided to the CODM.”

Governmental customers outside US

Non-US customers often governmental entities under government-sponsored healthcare systems

90%
Source evidence
“Because of the predominance of government-sponsored healthcare systems around the world, our customer relationships outside of the United States may be with governmental entities”

Distribution via distributors and payer programs

Products sold through distributors; participates in U.S. chargeback programs and financial assistance programs for users with commercial insurance

90%
Source evidence
“We record a provision for the incentive earned based on the number of estimated claims and our estimate of the cost per claim at the time of sale.”

Intermediary distribution channel

Distributes Omnipod via own direct sales force plus intermediaries; intermediary underperformance could delay market acceptance

92%
Source evidence
“In addition to promoting, marketing, and selling Omnipod products through our own direct sales force, we utilize intermediaries to distribute our product.”

Omnipod product platform concentration

Company derives nearly all revenue from the Omnipod product platform

99%
Source evidence
“We expect to continue to derive nearly all our revenue from our Omnipod product platform.”

Omnipod platform product family

Omnipod platform: Omnipod 5, Omnipod DASH, and Classic Omnipod

99%
Source evidence
“The Omnipod platform includes: the Omnipod® 5 Automated Insulin Delivery System (“Omnipod 5”), the Omnipod DASH® Insulin Management System (“Omnipod DASH”), and the Omnipod Insulin Management System (“Classic Omnipod”)”

Drug Delivery — Amgen Neulasta Onpro

Substantially all Drug Delivery revenue is sales of pods to Amgen for Neulasta Onpro kit; $34.1M (2025) vs $38.9M (2024)

97%
Source evidence
“Substantially all of our Drug Delivery revenue consists of sales of pods to Amgen for use in the Neulasta® Onpro® kit”

Non-insulin Drug Delivery product line — Amgen Neulasta Onpro

Drug Delivery line: substantially all revenue from customized Pods for Amgen's Neulasta Onpro kit; agreement expires December 2028

97%
Source evidence
“Substantially all of our commercialized Drug Delivery revenue consists of sales of a customized version of our product for use in Amgen’s Neulasta Onpro kit under an agreement that expires in December 2028.”

Drug Delivery product line revenue recognition

Modified Pod sold to a pharmaceutical company under firm purchase commitments; revenue recognized over time via percentage-of-completion; $34.1M in 2025

95%
Source evidence
“The Company’s Drug Delivery product line includes sales of a modified version of the Pod to a pharmaceutical company who use the Company’s technology as a delivery method for their drugs.”

Revenue by geography 2025 vs 2024

U.S. $1,919.8M (+27.2%); International $754.3M (+44.1%); Drug Delivery $34.1M (-12.3%); Total $2,708.1M (+30.7%, +29.5% cc) in 2025 vs 2024

98%
Source evidence
“Total revenue increased $636.6 million, or 30.7%, to $2,708.1 million in 2025, compared with $2,071.6 million in 2024”

Revenue by geography 2025/2024/2023

U.S. $1,953.9M / Int'l $754.3M in 2025; U.S. $1,548.2M / Int'l $523.4M in 2024; U.S. $1,287.0M / Int'l $410.1M in 2023; total 2025 $2,708.1M

97%
Source evidence
“U.S.$1,953.9 $1,548.2 $1,287.0 International754.3 523.4 410.1 Total revenue$2,708.1 $2,071.6 $1,697.1”

Disaggregated revenue by product line

Total Omnipod products $2,674.0M (U.S. $1,919.8M, Int'l $754.3M) and Drug Delivery $34.1M in 2025; total Omnipod $2,032.7M / Drug Delivery $38.9M in 2024; $1,661.1M / $36.0M in 2023

97%
Source evidence
“Total Omnipod products 2,674.0 2,032.7 1,661.1 Drug Delivery34.1 38.9 36.0 Total revenue$2,708.1 $2,071.6 $1,697.1”

Operations and dependencies

Malaysia and Costa Rica manufacturing plants

New Malaysia plant producing since 2024; investing in another plant in Costa Rica

96%
Source evidence
“We began producing product at our new manufacturing plant in Malaysia in 2024 and are already investing in another manufacturing plant in Costa Rica”

Long-lived assets (PP&E) by geography

PP&E net 2025: U.S. $472.5M, Malaysia $220.0M, China $74.1M, Other $52.9M; total $819.5M (2024 total $723.1M)

95%
Source evidence
“U.S. $472.5 $475.9 Malaysia220.0 159.1 China 74.1 78.5”

Single-source semiconductor chips

Each type of semiconductor chip is typically sourced from a single external supplier

95%
Source evidence
“The Company uses different types of semiconductor chips, which are sourced from external suppliers, in the manufacturing of its products. While the Company has multiple suppliers of semiconductor chips, each type is typically sourced from a single supplier.”

Employee base

~5,400 full-time employees as of Dec 31, 2025 (+38% YoY); ~60% in US, remainder in 17 other countries

98%
Source evidence
“As of December 31, 2025, we had approximately 5,400 full-time employees, representing a 38% increase over the prior year.”

Positioning and strategy

Insulin pump competitors

Competes with Medtronic Diabetes (being spun out), Tandem Diabetes Care, and Beta Bionics

97%
Source evidence
“We compete with established companies that produce insulin pumps, such as Medtronic Diabetes, a division of Medtronic plc (which division is being spun out into a new, independent publicly traded company), Tandem Diabetes Care Inc., as well as emerging companies like Beta Bionics Inc.”

Type 2 diabetes incidence rising among youth

Type 2 diabetes incidence increasing among children and young adults due primarily to increasing obesity

90%
Source evidence
“its incidence is increasing among children and young adults, due primarily to increasing obesity”

Growth drivers: Omnipod 5, international expansion, type 2 diabetes

Growth driven by increasing demand for Omnipod 5, international expansion, and entrance into insulin-requiring type 2 diabetes market

95%
Source evidence
“As we continue to expand the number of customers we serve, driven by increasing demand for Omnipod 5, our international expansion and entrance into the insulin-requiring type 2 diabetes market”

Addressable market estimates

Est. 6M type 1 + 6M insulin-requiring type 2 in served countries; 3M US basal-only type 2; ~40% US and ~25% international type 1 pump penetration

95%
Source evidence
“We estimate that approximately 40% of the type 1 diabetes population in the United States and 25% of the international type 1 diabetes population use insulin pump therapy.”

Pipeline: fully closed loop, Omnipod 6, Libre 3 Plus integration

Pipeline: fully closed loop AID for type 2 (EVOLUTION 2), Omnipod 6 next-gen AID, Abbott Libre 3 Plus integration

95%
Source evidence
“we completed STRIVE, our pivotal study for the next generation hybrid closed loop system, and we finished enrollment for EVOLUTION 2, our safety and feasibility study for a fully closed loop AID system for type 2 diabetes”

Type 2 diabetes market via Omnipod 5; Omnipod GO discontinued

FDA cleared Omnipod 5 for type 2 diabetes (Aug 2024); Omnipod GO commercialization dropped with $13.5M inventory charge in 2024

96%
Source evidence
“we made a strategic decision to drive growth in the type 2 diabetes market with Omnipod 5. Accordingly, we decided not to move forward with the commercialization of Omnipod GO”

Risks, financing, and outlook

Debt actions 2025

Issued 6.5% senior notes (Mar 2025); repurchased $419.9M convertible notes for $541.5M cash ($123.9M loss on extinguishment); interest expense $59.4M

96%
Source evidence
“we repurchased $419.9 million million in principal ($417.6 million net of issuance costs) of our Convertible Senior Notes for $541.5 million in cash, which resulted in a $123.9 million loss on extinguishment”

Tariff exposure — medical device exemption

Loss of current medical device tariff exemption would have a material impact on results in future years

90%
Source evidence
“should the exemption that is currently in place for certain medical devices be eliminated, tariffs would have a material impact on our results of operations in future years”

2026 outlook

2026: strong U.S. and International revenue growth expected; net interest expense to increase to $40M+; tariff exemption loss would be material in future years

94%
Source evidence
“In 2026, we expect strong U.S. revenue growth primarily driven by the benefits of our recurring revenue model and continued volume growth of Omnipod 5”

ACA continuing impact

Expects ACA to continue significantly impacting US healthcare delivery and business near term

85%
Source evidence
“pect that the ACA will continue to have a significant impact on the delivery of healthcare in the United States and on our business in the near term”

EU MDR / CE Mark status

CE Mark under MDR and UKCA for Omnipod 5/DASH; Classic Omnipod sellable through 2027 under MDD

97%
Source evidence
“We have obtained the right to affix the CE Mark under MDR, and UK Conformity Assessed (UKCA marking) to Omnipod 5 and Omnipod DASH”

Healthcare fraud and abuse laws exposure

Subject to Anti-Kickback Statute, False Claims Act, and related laws; violations could bring penalties and exclusion from federal healthcare programs

94%
Source evidence
“These laws include, among others, the federal healthcare Anti-Kickback Statute, the federal civil False Claims Act, other federal healthcare false statement and fraud statutes, the Open Payments program, the Civil Monetary Penalties Law”

Anti-bribery laws (FCPA, U.K. Bribery Act)

FCPA and U.K. Bribery Act exposure; most non-U.S. customer relationships are with governmental entities

93%
Source evidence
“Because of the predominance of government-sponsored healthcare systems around the world, most of our customer relationships outside of the United States are with governmental entities and are therefore subject to such anti-bribery laws.”

AI regulation exposure

Subject to EU AI Act (provisions through Aug 2026) and emerging US state AI laws; AI deployed in operations

90%
Source evidence
“The Cybersecurity Directive and the Artificial Intelligence Act (“EU AI Act”) was enacted in August 2024, with provisions taking effect through August 2026.”

Physician Payments Sunshine Act

Sunshine Act/Open Payments reporting to CMS with penalty risk

90%
Source evidence
“requires manufacturers of drugs and devices for which payment is available under Medicare, Medicaid, or the Children’s Health Insurance Program”

Anti-bribery laws

FCPA, U.K. Bribery Act, and similar anti-bribery laws apply given government-sponsored healthcare systems abroad

90%
Source evidence
“We are subject to the FCPA in the United States. and to similar anti-bribery laws in other jurisdictions”

Environmental/ESG disclosure regulation

California climate disclosure and EU CSRD reporting requirements; customer environmental procurement policies

88%
Source evidence
“including California’s climate disclosure requirements, and similar regulations established by other international regulatory bodies, such as the Corporate Sustainability Reporting Directive in the European Union”

Third-party payor reimbursement risk

Sales depend on third-party payor coverage/reimbursement; Medicare Part D covers Omnipod through pharmacy channel; payor contracts terminable without cause

95%
Source evidence
“Medicare Part D Plan Sponsors may provide coverage for Omnipod products under the Medicare Part D prescription drug program, which requires negotiating with third-party payors in order to provide our product through the pharmacy channel in the United States.”

Customer retention dependency

Revenue growth depends on retaining a high percentage of customers; failure to retain would negatively impact revenue growth

95%
Source evidence
“A key to driving our revenue growth is the retention of a high percentage of our customers.”

Manufacturing and regulatory (QSR) risk including contract manufacturer

FDA QSR inspections (sometimes unannounced) of company and contract manufacturer facilities; failure could delay production and trigger recalls/enforcement

94%
Source evidence
“is monitored rigorously through periodic, sometimes unannounced, inspections by the FDA”

Privacy, data protection, and AI regulation exposure

Subject to HIPAA, CCPA/CPRA, GDPR, and EU AI Act (phased through August 2026); uses generative AI tools in operations

93%
Source evidence
“including the EU AI Act (which is taking effect in stages, through August 2026)”

GLP-1 and diabetes cure research obsolescence risk

GLP-1 adoption and breakthrough diabetes research (e.g., Vertex Pharmaceuticals, NIH) could reduce the market for Omnipod products

93%
Source evidence
“Further, increased availability and adoption of the GLP-1 class of drugs may delay the progression of type 2 diabetes in obese patients.”

Product recall and malfunction risk

Product malfunctions could lead to recalls, safety alerts, litigation, substantial costs, and reputational damage

92%
Source evidence
“Adverse events involving our products have been reported to us in the past, and we cannot guarantee that they will not occur in the future.”

Cybersecurity and IT systems risk

Relies on IT systems and product security; a successful cyber-attack or breach could have a material adverse effect

90%
Source evidence
“We rely on IT systems to process, transmit, and store electronic information, including personal, financial, and sensitive medical information.”

GLP-1 / SGLT2 alternative therapies

Competing non-insulin drug therapies (SGLT2 inhibitors, GLP-1 drugs) precede insulin therapy in type 2 care pathway

85%
Source evidence
“medications, both oral and injectable, including SGLT2 inhibitors and GLP-1 drugs”

Material exposure graph

Omnipod product platform
Revenue Exposure

Nearly all company revenue derives from the Omnipod product platform; success in marketing/selling it determines financial results.

Relevance 100·Dependency 100·Confidence 99
Source evidence
“We expect to continue to derive nearly all our revenue from our Omnipod product platform.”
Omnipod Products
Revenue Exposure

Omnipod products generate nearly all revenue: $2,674.0M of $2,708.1M total in 2025

Relevance 100·Dependency 99·Confidence 98
Source evidence
“Total Omnipod Products2,674.0 2,032.7 31.6 %1.2 %30.3 %”
Third-party payors (Medicare, Medicaid, private insurers)
Customer Exposure

Sales are limited unless third-party payors pay a substantial portion of the sales price; contracts terminable without cause, and legislative changes could affect demand and pricing.

Relevance 95·Dependency 90·Confidence 95
Source evidence
“We expect that sales of our Omnipod products would be limited if a substantial portion of their sales price is not paid for by third-party payors”
Distributors A, B, C
Customer Exposure

Three distributors each represent 25%+ of 2025 revenue (78% combined), concentrating revenue and receivables risk.

Relevance 90·Dependency 75·Confidence 95
Source evidence
“Distributor A27%28%28% Distributor B26%26%24% Distributor C25%21%19%”
semiconductor chips
Supplier Dependency

Single-sourced semiconductor chip types embed into Omnipod products; supply disruption could halt manufacturing and sales.

Relevance 85·Dependency 80·Confidence 95
Source evidence
“Supply chain disruptions, supplier shortages, logistic delays, or quality problems could result in manufacturing delays, increased costs, or a possible loss of sales”
Medicare / Medicaid regulation
Regulatory Exposure

Compliance with Medicare/Medicaid regulations is subject to review by OIG, CMS, and DOJ; legislative changes affecting Medicare, Medicaid, and the ACA could adversely affect demand and pricing.

Relevance 85·Dependency 75·Confidence 94
Source evidence
“we anticipate that recently enacted and proposed legislative changes affecting Medicare, Medicaid, and the Affordable Care Act may impact healthcare coverage, which, if implemented could adversely affect both demand for and pricing of our products”
EU Medical Device Regulation (MDR)
Regulatory Exposure

CE Mark under MDR and UKCA enables EU/UK distribution of Omnipod 5 and DASH; Classic Omnipod MDD route ends in 2027, creating a transition deadline.

Relevance 80·Dependency 75·Confidence 97
Source evidence
“can continue to sell Classic Omnipod through 2027 in the European Union and in other countries that recognize the CE Mark”
Dexcom, Inc.
Technology Dependency

Omnipod 5 integrates with Dexcom G6 and G7 CGMs; CGM is sold separately by third parties

Relevance 80·Dependency 65·Confidence 95
Source evidence
“The Pod currently integrates with Dexcom, Inc.’s G6 and G7 CGMs and with Abbott Diabetes Care, Inc.’s (“Abbott”) FreeStyle Libre 2 Plus sensor”
Medtronic Diabetes
Competitive Exposure

Medtronic Diabetes is a named established insulin pump competitor (division being spun out); superior competing products could inhibit ability to compete.

Relevance 80·Dependency 60·Confidence 95
Source evidence
“We compete with established companies that produce insulin pumps, such as Medtronic Diabetes, a division of Medtronic plc”
Tandem Diabetes Care Inc.
Competitive Exposure

Tandem Diabetes Care is a named established insulin pump competitor; competitor innovations or pricing changes could create pressure.

Relevance 75·Dependency 55·Confidence 95
Source evidence
“Tandem Diabetes Care Inc., as well as emerging companies like Beta Bionics Inc.”
Amgen (Neulasta Onpro Drug Delivery agreement)
Revenue Exposure

Substantially all commercialized non-insulin Drug Delivery revenue comes from a customized Pod for Amgen's Neulasta Onpro kit under an agreement expiring December 2028; termination would negatively impact financial results.

Relevance 70·Dependency 85·Confidence 95
Source evidence
“if our agreement with Amgen is terminated or not renewed, our financial results could be negatively impacted”
Abbott Diabetes Care, Inc.
Technology Dependency

Omnipod 5 integrates with Abbott's FreeStyle Libre 2 Plus in various markets; integrating Libre 3 Plus; also used in RADIANT study

Relevance 70·Dependency 55·Confidence 93
Source evidence
“with Abbott’s FreeStyle Libre 2 Plus sensor in Australia... We are currently working to integrate Omnipod 5 with Abbott’s FreeStyle Libre 3 Plus”
GLP-1 drugs
Revenue Exposure

SGLT2 inhibitors and GLP-1 drugs are alternatives in type 2 diabetes management before insulin therapy, affecting future insulin-dependent patient funnel.

Relevance 70·Dependency 40·Confidence 85
Source evidence
“medications, both oral and injectable, including SGLT2 inhibitors and GLP-1 drugs”
Malaysia
Manufacturing Dependency

New manufacturing plant in Malaysia began production in 2024, supporting global supply

Relevance 65·Dependency 55·Confidence 94
Source evidence
“We began producing product at our new manufacturing plant in Malaysia in 2024”
GLP-1 class drugs
Demand Driver

Increased availability and adoption of GLP-1 drugs may delay type 2 diabetes progression in obese patients, potentially reducing future demand for Omnipod products.

Relevance 65·Dependency 40·Confidence 90
Source evidence
“increased availability and adoption of the GLP-1 class of drugs may delay the progression of type 2 diabetes in obese patients”
Privacy/data protection laws (HIPAA, CCPA/CPRA, GDPR, EU AI Act)
Regulatory Exposure

Complex evolving privacy, data protection, and AI regulations (including EU AI Act phased through August 2026) could result in legal claims, monetary penalties, and increased operating costs.

Relevance 60·Dependency 55·Confidence 93
Source evidence
“If we fail to comply with these standards, we could be subject to criminal penalties and civil sanctions, including significant fines and penalties.”
Tariffs
Regulatory Exposure

Elimination of current medical device tariff exemption would materially impact results in future years

Relevance 60·Dependency 40·Confidence 88
Source evidence
“should the exemption that is currently in place for certain medical devices be eliminated, tariffs would have a material impact on our results of operations in future years”
Drug Delivery product line
Revenue Exposure

Drug Delivery depends on one pharmaceutical customer with firm purchase commitments; inventory has no alternative use, recognized over time.

Relevance 55·Dependency 60·Confidence 90
Source evidence
“the product is produced pursuant to the customer’s firm purchase commitments, the Company has an enforceable right to payment for performance completed to date, and the inventory has no alternative use to the Company”
customer pricing incentives
Cost Driver

Chargebacks, distributor fees, returns, discounts, and financial assistance provisions reduce transaction price and thus net revenue.

Relevance 55·Dependency 45·Confidence 85
Source evidence
“These fees are not in exchange for a distinct good or service and therefore are recognized as a reduction of the transaction price.”
Costa Rica
Manufacturing Dependency

Investing in a new manufacturing plant in Costa Rica to support continued growth

Relevance 55·Dependency 40·Confidence 90
Source evidence
“are already investing in another manufacturing plant in Costa Rica to support our continued growth”
Amgen
Customer Exposure

Substantially all Drug Delivery revenue is pod sales to Amgen for the Neulasta Onpro kit ($34.1M in 2025)

Relevance 55·Dependency 35·Confidence 95
Source evidence
“Substantially all of our Drug Delivery revenue consists of sales of pods to Amgen for use in the Neulasta® Onpro® kit”
Amgen
Customer Exposure

Insulet produces pods for Amgen's Neulasta Onpro kit, a secondary revenue stream alongside the Omnipod diabetes business.

Relevance 55·Dependency 20·Confidence 95
Source evidence
“We also produce pods for Amgen for use in the Neulasta® Onpro® kit”
commercial insurance coverage
Demand Driver

Insulet offers financial assistance programs for users with commercial insurance, indicating payer coverage affects end-user demand economics.

Relevance 50·Dependency 40·Confidence 70
Source evidence
“including but not limited to financial assistance programs for users with commercial insurance”
Full company information
Latest profile, trading, valuation, and identifier data stored for PODD.
Share price
$165.02
Market cap
$11.44B
Exchange
NASDAQ
Currency
USD
CEO
Ashley McEvoy
Employees
5,400
IPO date
15/05/2007
Beta
1.058
Last dividend
$0.00
Day range
$148.61 – $165.36
52-week range
$126.40 – $354.88
1-day performance
6.56%
1-year performance
30.55%
Current drawdown (1Y)
-53.50%
CIK
0001145197
CUSIP
45784P101
ISIN
US45784P1012
Created
07/12/2025, 05:48:31
Last update
05/11/2026, 01:27:04

Track Insulet Corp. with an AI analyst

See which prediction-market events move PODD, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to PODD from your Railway `news_articles` table.

Insulet Corporation (PODD) Discusses Recent Product Recalls and Physician Community Response at ADA Meeting Transcript

Seeking Alpha • STOCK • 12/06/2026, 21:12:09

Why Insulet (PODD) is a Top Momentum Stock for the Long-Term

Zacks Investment Research • STOCK • 11/06/2026, 12:52:05

Insulet (NASDAQ:PODD) Stock Analysis: Price Target Adjustment Amidst Strong Financial Growth and Market Volatility

Market Data • Market Data • 08/06/2026, 23:11:34

Insulet Corporation Valuation Pressure Has Dropped Enough (Upgrade)

Seeking Alpha • STOCK • 08/06/2026, 16:40:09

Insulet Corporation (PODD) Presents at 46th Annual William Blair Growth Stock Conference Transcript

Seeking Alpha • STOCK • 03/06/2026, 19:22:02

Insulet (NASDAQ:PODD) Stock Analysis: Omnipod Correction, Price Targets, and Valuation Insights

Market Data • Market Data • 28/05/2026, 20:00:25

Insulet Corporation (PODD) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 13/05/2026, 16:50:46

Insulet (NASDAQ: PODD) Shines with Strong Q1 Results Amidst Analyst Caution

Market Data • Market Data • 06/05/2026, 20:08:49

Insulet Corporation (PODD) Q1 2026 Earnings Call Transcript

Seeking Alpha • STOCK • 06/05/2026, 14:51:20

Insulet (PODD) Loses 17.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks Investment Research • STOCK • 06/05/2026, 12:35:40

Insulet lifts annual revenue forecast after quarterly beat on strong insulin pump demand

Reuters • STOCK • 06/05/2026, 09:46:00

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insulet Corporation - PODD

GlobeNewsWire • STOCK • 07/04/2026, 19:06:00